Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PLAAT5 | Q96KN8 | 4/20 | 0.56 |
| ▸ | PLAAT4 | Q9UL19 | 4/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | PLAAT3 | P53816 | 3/20 | 0.55 |
| ▸ | PLAAT2 | Q9NWW9 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313265 | 0.90 | FFAR1 (0.61) | PLAAT5PLAAT4PLAAT3PLAAT2HDAC2 | |
| SCHEMBL7640251 | 0.89 | PLAAT3 (0.58) | ALDH1A1PLAAT5PLAAT4PLAAT3PLAAT2 | |
| SCHEMBL7634822 | 0.87 | PLAAT3 (0.59) | PLAAT5PLAAT4PLAAT3PLAAT2HDAC2 | |
| SCHEMBL20897266 | 0.87 | KEAP1 (0.55) | ALDH1A1PLAAT5PLAAT4KEAP1PLAAT3 | |
| SCHEMBL7643149 | 0.86 | MAPT (0.61) | PLAAT5PLAAT4PLAAT3PLAAT2HDAC2 | |
| SCHEMBL7641938 | 0.86 | MAPT (0.61) | PLAAT5PLAAT4PLAAT3PLAAT2HDAC2 | |
| SCHEMBL6943718 | 0.83 | PLAAT5 (0.48) | ALDH1A1PLAAT5PLAAT4KEAP1PLAAT3 | |
| SCHEMBL9296831 | 0.83 | PLAAT5 (0.48) | ALDH1A1PLAAT5PLAAT4KEAP1PLAAT3 | |
| SCHEMBL8748206 | 0.83 | PLAAT5 (0.48) | ALDH1A1PLAAT5PLAAT4KEAP1PLAAT3 | |
| SCHEMBL12396191 | 0.82 | ALDH1A1 (0.50) | ALDH1A1PLAAT5PLAAT4PLAAT3PLAAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104250236-B | γ hydrocarbon oxygen sulfonylmethyl gamma butyrolactone, the synthetic method of δ hydrocarbon oxygen sulfonylmethyl δ valerolactone | 大连大学 | 2017-03-01 | — | — | CN | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| CN-102906261-A | Mutant reductase | SUMITOMO CHEMICAL CO | 2013-01-30 | — | — | CN | disclosed |
| WO-2011009849-A2 | METHOD FOR PREPARING OPTICALLY ACTIVE HYDROXY ACID ESTERS | BASF SE (DE) | 2011-01-27 | — | — | WO | disclosed |
| EP-1437401-B1 | Oxidoreductase | IEP GMBH (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | THADANI AVINASH N | 2010-07-08 | — | — | US | disclosed |
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | THADANI AVINASH N | 2010-07-08 | — | — | US | disclosed |
| EP-1762625-B1 | Reductase gene and use thereof | SUMITOMO CHEMICAL CO (JP) | 2009-07-15 | — | — | EP | disclosed |
| US-7524666-B2 | Reductase gene and use thereof | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-5098892-A | Angiotensin converting enzyme inhibitors as hypotensive agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| US-4822818-A | ANTIHYPERTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| US-4661479-A | ENZYME INHIBITORS | MERCK AND CO., INC. (US) | 1987-04-28 | — | — | US | disclosed |
| US-4617301-A | Sulfoxide and sulfone derivatives of bicyclic lactams as antihypertensives | MERCK & CO., INC. (US) | 1986-10-14 | — | — | US | disclosed |
| EP-0061187-B1 | BICYCLIC LACTAMS AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| US-4474692-A | L-Alanyl-N-(indan-2-yl)glycine, its esters and salts thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-10-02 | — | — | US | disclosed |
| EP-0051391-B1 | BICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-09-05 | — | — | EP | disclosed |
| US-4415496-A | HYPOTENSIVE AGENTS; 5-OXOTHIAZOLO/3,2-A/AZEPINE DERIVATIVES FROM A PHTHALIMIDE | MERCK & CO., INC. (US) | 1983-11-15 | — | — | US | disclosed |
| EP-0061187-A1 | Bicyclic lactams as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| EP-0051391-A1 | Bicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | HNMT, AADAT, DAO | ALDH1A1 509/4885PLAAT5 2695/4885PLAAT4 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.